NN 3201
Alternative Names: NN-3201Latest Information Update: 15 Jun 2024
At a glance
- Originator Novelty Nobility
- Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 Apr 2024 Adverse events and pharmacodynamics data from preclinical studies in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 14 Apr 2023 Adverse events and pharmacodynamics data from preclinical studies in Cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 27 Apr 2022 NN 3201 is available for licensing as of 27 Apr 2022. http://www.noveltynobility.com/news/media.php